Without ACE2, Angiotensin II causes contraction of smooth muscle via the phosphodiesterase 5 (PDE5) pathway (4) with vasoconstriction and cough. ACE2 converts inactivates Angiotensin II to Angiotensin 1-7.(3). SARS-COV-2 targets ACE2 and, while reduced expression of ACE2 has not been shown, the assumption of such a reduction is consistent with clinical findings. This review of some pharmacological interventions (1) is a helpful summary but it restricts itself, perhaps based on the methodology, to interventions directed toward SARS-COV-2 virus itself and so does not include potential interventions to mitigate the clinical effects of COVID-19. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography.